"The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency&rsq"...
Zevalin Patient Information including How Should I Take
In this Article
- What is ibritumomab (Zevalin)?
- What are the possible side effects of ibritumomab (Zevalin)?
- What is the most important information I should know about ibritumomab (Zevalin)?
- What should I discuss with my healthcare provider before receiving ibritumomab (Zevalin)?
- How is ibritumomab used (Zevalin)?
- What happens if I miss a dose (Zevalin)?
- What happens if I overdose (Zevalin)?
- What should I avoid while using ibritumomab (Zevalin)?
- What other drugs will affect ibritumomab (Zevalin)?
- Where can I get more information?
What should I discuss with my healthcare provider before receiving ibritumomab (Zevalin)?
You should not receive this medication if you are allergic to ibritumomab, or to radioactive chemicals or mouse proteins.
Before you receive ibritumomab, tell your doctor if you are allergic to any drugs, or if you have:
- liver disease;
- kidney disease;
- any type of infection;
- lung or breathing problems;
- bleeding or blood clotting problems;
- low platelet counts;
- low blood pressure; or
- a history of heart disease, heart attack, angina (chest pain), or irregular heart beats.
If you have any of these conditions, you may need a dose adjustment or special tests to safely receive ibritumomab.
FDA pregnancy category D. This medication can cause harm to an unborn baby. Do not receive ibritumomab if you are pregnant. Tell your doctor if you become pregnant during treatment. Use an effective form of birth control while you are receiving this medication.
It is not known whether ibritumomab passes into breast milk or if it could harm a nursing baby. Do not receive ibritumomab without telling your doctor if you are breast-feeding a baby.
Ibritumomab is made from human plasma (part of the blood) and may contain viruses and other infectious agents that can cause disease. Although donated human plasma is screened, tested, and treated to reduce the risk of it containing anything that could cause disease, there is still a small possibility it could transmit disease. Talk with your doctor about the risks and benefits of using this medication.
Some people receiving ibritumomab have developed "secondary" bone marrow or blood cell cancers such as leukemia. Talk with your doctor about your individual risk while receiving this medication.
How is ibritumomab used (Zevalin)?
Ibritumomab is used in combination with rituximab (Rituxan) and a radioactive chemical. Ibritumomab is given as an injection through a needle placed into a vein. Your doctor, nurse, or other healthcare provider will give you this injection.
Ibritumomab is usually given every 7 to 9 days. Follow your doctor's instructions.
Ibritumomab can lower the blood cells that help your body fight infections. This can make it easier for you to bleed from an injury or get sick from being around others who are ill. To be sure your blood cells do not get too low, your blood will need to be tested on a regular basis. Do not miss any scheduled appointments.
Additional Zevalin Information
Zevalin - User Reviews
Zevalin User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.